Dupilumab treatment was associated with improved bone growth and bone mineral density in children with eczema, according to a study published in the Journal of the American Academy of Dermatology.

Among infants with eosinophilic esophagitis aged younger than 1 year or weighing less than 15 kg, esophageal eosinophilia and ...

The current standard of care for food allergy focuses on strict avoidance of the offending allergen and the prompt use of an ...

Formycon AG (“Formycon”) announced its partnership with OneSource Specialty Pharma Limited (“One Source”) on July 14, 2026. OneSource, located ...

Dupilumab's growth is driven by its established market presence, new indications like COPD, broad multi-indication use, and strong clinical performance. Recent approvals and phase III trial successes, ...

Wall Street analysts forecast that Regeneron (REGN) will report quarterly earnings of $10.00 per share in its upcoming ...

The food allergy market landscape is advancing through a robust clinical pipeline, with key programs being developed by companies such as DBV Technologies (Viaskin [DBV712] Peanut Patch), Novartis ...

Dupixent is already a leading biologic, underpinning sustainable growth. Sanofi and Regeneron Pharmaceuticals reported Dupixent sales of €10.7 billion in 2023, marking a 31% year-over-year increase.

Mepolizumab is a monoclonal antibody that targets interleukin-5, a key cytokine in eosinophilic inflammation. The MATINEE ...

USA: Researchers have found in a new study that treatment with abrocitinib enabled more patients with atopic dermatitis to ...

11-center CEGIR network study led by Cincinnati Children's advances our understanding of eosinophilic gastritis – a rare inflammatory food allergic disease of the stomach – and potentially opens ...

A LITTLE girl who was unable to smile due to agonising eczema has been given her childhood back after going through a ...